LEADER 05321nam  2200721 a 450 
001 9910456246503321
005 20200520144314.0
010   $a1-281-30039-X
010   $a9786611300395
010   $a0-309-11575-2
035   $a(CKB)2450000000000828
035   $a(EBL)3378345
035   $a(SSID)ssj0000400539
035   $a(PQKBManifestationID)12112065
035   $a(PQKBTitleCode)TC0000400539
035   $a(PQKBWorkID)10394776
035   $a(PQKB)10074069
035   $a(SSID)ssj0000304393
035   $a(PQKBManifestationID)12115291
035   $a(PQKBTitleCode)TC0000304393
035   $a(PQKBWorkID)10278838
035   $a(PQKB)10571356
035   $a(MiAaPQ)EBC3378345
035   $a(Au-PeEL)EBL3378345
035   $a(CaPaEBR)ebr10225189
035   $a(OCoLC)923278682
035   $a(EXLCZ)992450000000000828
100   $a19840919d1985      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aDiseases of importance in the United States$b[electronic resource] /$fby the Committee on Issues and Priorities for New Vaccine Development, Division of Health Promotion and Disease Prevention, Institute of Medicine
210   $aWashington, D.C. $cNational Academy Press$d1985
215   $a1 online resource (472 p.)
225 0 $aNew vaccine development : establishing priorities ;$vv. 1
300   $aPrepared for the National Institute of Allergy and Infectious Diseases.
311   $a0-309-03494-9 
320   $aIncludes bibliographical references and index.
327   $a""Title""; ""Copyright""; ""Acknowledgments""; ""Preface""; ""Abstract""; ""Contents""; ""1 Summary""; ""Selection of Candidates""; ""Determination of Health Benefits""; ""Disease Burden Estimates""; ""Infant Mortality Equivalence Values""; ""Total Disease Burden Values""; ""Vaccine Characteristics""; ""Predictions of Vaccine Development""; ""Definition of Probable Vaccine Target Population""; ""Estimation of Vaccine Utilization""; ""Estimation of Time to Licensure, Time to vaccine Adoption, and Delay of Vaccination Benefits: Discounting""; ""Estimation of vaccine Preventable Illness""
327   $a""Calculation of Expected Health Benefits for Each Vaccine""""Cost Calculations""; ""Calculation of Morbidity Costs Averted by the Vaccine""; ""Vaccination Program Costs""; ""Integration of Costs""; ""Interpretation of Health Benefit and Net Cost Rankings""; ""Findings, Conclusions, Recommendations""; ""Recommendation""; ""Reference""; ""2 Priority Setting for Health Related Investments: A Review of Methods""; ""Methods for Project Ranking and Selection""; ""Multiattribute Accounting""; ""Multiattribute Scoring""; ""Decision Analysis With Multiple Objectives""
327   $a""Cost-Effectiveness and Cost-Utility Analysis""""Benefit-Cost Analysis""; ""Selection of an Approach""; ""Issues in Project Ranking Methodologies""; ""Sources of Estimates""; ""Sequential or a???Lexicographica??? Methods""; ""Interdependence Among Projects""; ""The a???Portfolioa??? Question""; ""Summary""; ""References""; ""3 Overview of the Analytic Approach""; ""Method""; ""Interpretation of Results""; ""Guidelines""; ""Definition of Dominance""; ""Step 1""; ""Step 2""; ""Step 3""; ""Step 4""; ""Summary""; ""4 Comparison of Disease Burdens and Costs""
327   $a""Elements of the System for Comparing Morbidity and Mortality Burdens Arising From various Diseases""""Trade-Off Values""; ""Expression of Morbidity and Mortality Burdens""; ""Procedures Used in Deriving Disease Estimates""; ""Limitations of the Current Estimates""; ""Value Judgments in Quantifying Morbidity and Mortality""; ""IME Perspectives used in This Study""; ""The Effect of Adopting Other IME Perspectives""; ""Comparison of Direct Costs Resulting from Diseases""; ""Scope of Cost Calculations""; ""Procedures""; ""Findings""; ""Limitations of the Proposed System""
327   $a""Summary and Conclusions""""Recommendations""; ""References""; ""5 Predictions on Vaccine Development""; ""The Need for Predictions""; ""Selection of Candidates""; ""Vaccine Candidates and Target Populations""; ""Predictions on Vaccine Development""; ""Probability of Successful Development""; ""Cost of Development""; ""Time to Licensure""; ""Comments""; ""Predictions on Vaccine Characteristics""; ""Efficacy""; ""Adverse Reactions""; ""Production Technology, Delivery Requirements, and Cost/Dose""; ""Number of Doses and Route of Administration""; ""Conclusions""
327   $a""6 Assessing the Likely Utilization of New Vaccines""
606   $aVaccines$xResearch$xGovernment policy
606   $aVaccination$zUnited States
606   $aVaccination$zDeveloping countries
608   $aElectronic books.
615  0$aVaccines$xResearch$xGovernment policy.
615  0$aVaccination
615  0$aVaccination
676   $a614.4/7/0973
712 02$aInstitute of Medicine (U.S.).$bCommittee on Issues and Priorities for New Vaccine Development.
712 02$aNational Institute of Allergy and Infectious Diseases (U.S.)
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910456246503321
996   $aDiseases of importance in the United States$91977210
997   $aUNINA